ÂÜÀòÂÒÂ×

Tom Bumol is an experienced biopharmaceutical executive with a distinguished career spanning over four decades. Currently serving as a member of the Board of Directors for multiple organizations, including Tentarix Biotherapeutics, Spine BioPharma, and Omeros Corporation, Tom also contributes to scientific advisory boards for CytoReason, Neurocrine Biosciences, and ProFound Therapeutics. Previously, Tom held key leadership roles such as Executive Vice President at the Allen Institute for Immunology and Senior Vice President of Biotechnology and Immunology Research at Eli Lilly, where tenure included various positions over 25 years. Tom's academic credentials include a B.S. in Microbiology from the University of Michigan and a Ph.D. in Microbiology/Immunology from the University of Minnesota.